NAFLD/NASH

Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, termed steatosis. Non-alcoholic steatohepatitis (NASH) occurs when steatosis progresses, causing inflammation and liver tissue injury, which can lead to hepatocyte death, fibrosis, inflammation, and scarring (cirrhosis). NAFLD is the most prevalent chronic liver disease in the United States, affecting approximately 25% of adults.

DiaPharma offers a diverse portfolio of ELISA assays for measuring blood-based biomarkers in liver research studies. Utilization of these biomarkers provides a non-invasive and accessible testing option to assess liver function and evaluate NAFLD and NASH disease mechanisms. These biomarkers are currently being investigated to further understand the pathogenesis of NAFLD and NASH liver diseases and to evaluate response to treatment in clinical trial and research settings.  Read more details…

Other Liver Diseases

Antibodies

Animal Assays

DILI/Hepatotoxicity

Read more about drug-induced liver injury (DILI), hepatotoxicity, and emerging exploratory biomarkers for drug safety studies.

ALD/AH

Alcohol-associated Liver Disease

Alcohol-associated liver disease (ALD) is a spectrum of alcohol-driven hepatic disorders that range from steatosis, hepatitis, fibrosis, and ultimately cirrhosis. Alcohol-associated hepatitis (AH) is a severe form of acute liver inflammation that causes tissue damage and cell death.  It is associated with high rates of short-term mortality.

DiaPharma offers a variety ELISA assays for measuring blood-based biomarkers in liver research studies. Measuring these biomarkers provides a non-invasive testing approach in the evaluation of liver function and disease mechanisms. Non-invasive testing methods are often used as more accessible alternatives to the standard liver biopsy in research settings. These biomarkers are currently being investigated for use in ALD and AH research and clinical trials to further understand the pathogenesis of alcohol-associated liver diseases and liver responses to ALD therapies.  Read more details…

All Liver